Literature DB >> 15163256

Clozapine and hypertension: a chart review of 82 patients.

David C Henderson1, Tara B Daley, Laura Kunkel, Myisha Rodrigues-Scott, Pamposh Koul, Doug Hayden.   

Abstract

OBJECTIVE: Clozapine has been linked to significant weight gain and increase in serum lipids and appears to negatively impact glucose metabolism. In this retrospective chart review study, we examine changes in systolic and diastolic blood pressure and treatment for hypertension in clozapine-treated patients.
METHOD: Data on demographics and systolic and diastolic blood pressure were examined for up to 5 years (September 1987 to September 1992) in 82 patients treated with clozapine. Rates of hypertension treatment in clozapine-treated patients were compared with patients receiving conventional antipsychotics (N = 56) and other atypical antipsychotic agents (N = 102).
RESULTS: The mean age of the 82 patients at the time of clozapine initiation was 36.4 +/- 7.8 years, with 22 (27%) female, 75 (91%) white, 3 (4%) black, 3 (4%) Hispanic, and 1 (1%) Asian. The baseline weight was 175.5 +/- 34.0 lb (79.0 +/- 15.3 kg) and baseline body mass index was 26.9 +/- 5.0 kg/m(2). There was a significant increase in systolic blood pressure (p =.0004) and diastolic blood pressure (p =.0001). Overall, 22 patients (27%) received treatment for hypertension following clozapine initiation. Only 2 (4%) of 56 patients in the conventional antipsychotic group and 9 (9%) of 102 patients in the other atypical antipsychotic group (olanzapine, N = 6; risperidone, N = 3) received treatment for hypertension.
CONCLUSION: Our findings suggest that long-term clozapine treatment is associated with increased rates of hypertension, which may have a significant impact on medical morbidity and mortality.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15163256     DOI: 10.4088/jcp.v65n0514

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  18 in total

Review 1.  Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine.

Authors:  Domenico De Berardis; Gabriella Rapini; Luigi Olivieri; Domenico Di Nicola; Carmine Tomasetti; Alessandro Valchera; Michele Fornaro; Fabio Di Fabio; Giampaolo Perna; Marco Di Nicola; Gianluca Serafini; Alessandro Carano; Maurizio Pompili; Federica Vellante; Laura Orsolini; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Ther Adv Drug Saf       Date:  2018-02-06

2.  Prevalence and associations of the metabolic syndrome among patients prescribed clozapine.

Authors:  M Ahmed; I Hussain; S M O'Brien; B Dineen; D Griffin; C McDonald
Journal:  Ir J Med Sci       Date:  2008-05-07       Impact factor: 1.568

3.  A methodology for conducting retrospective chart review research in child and adolescent psychiatry.

Authors:  Robin E Gearing; Irfan A Mian; Jim Barber; Abel Ickowicz
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2006-08

Review 4.  The renal dopaminergic system: novel diagnostic and therapeutic approaches in hypertension and kidney disease.

Authors:  Ines Armando; Prasad Konkalmatt; Robin A Felder; Pedro A Jose
Journal:  Transl Res       Date:  2014-07-25       Impact factor: 7.012

5.  A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia.

Authors:  D C Henderson; X Fan; B Sharma; P M Copeland; C P Borba; R Boxill; O Freudenreich; C Cather; A Eden Evins; D C Goff
Journal:  Acta Psychiatr Scand       Date:  2009-01-12       Impact factor: 6.392

6.  Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine.

Authors:  David C Henderson; Xiaoduo Fan; Bikash Sharma; Paul M Copeland; Christina P C Borba; Oliver Freudenreich; Corinne Cather; A Eden Evins; Donald C Goff
Journal:  J Psychiatr Pract       Date:  2009-07       Impact factor: 1.325

Review 7.  Adverse effects of atypical antipsychotics : differential risk and clinical implications.

Authors:  Peter M Haddad; Sonu G Sharma
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

8.  Blood Pressure and Heart Rate Changes During Clozapine Treatment.

Authors:  Sarah M Norman; Kelli M Sullivan; Fang Liu; Bethany A DiPaula; Pedro A Jose; Christopher A Kitchen; Stephanie M Feldman; Deanna L Kelly
Journal:  Psychiatr Q       Date:  2017-09

9.  Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia.

Authors:  X Fan; C P C Borba; P Copeland; D Hayden; O Freudenreich; D C Goff; D C Henderson
Journal:  Acta Psychiatr Scand       Date:  2012-09-04       Impact factor: 6.392

Review 10.  Secondary hypertension: interfering substances.

Authors:  Ehud Grossman; Franz H Messerli
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-07       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.